Engage Bio
Engage Bio has developed Tethosomes, a new class of non-viral DNA which finally unleashes potent, durable, redosable, and scalable genetic medicine. In 2026 Engage was acquired by Eli Lilly.
Y Combinator
yc-company-directory #5108Engage Bio has developed Tethosomes, a new class of non-viral DNA which finally unleashes potent, durable, redosable, and scalable genetic medicine. In 2026 Engage was acquired by Eli Lilly.
sourceEngage Bio is classified as Other from source descriptions and fund-directory context. Similar companies below are ranked from offline product facets and meaningful description overlap; category and source affiliation can only strengthen an existing product match. For lookup-created rows, the profile starts as pending enrichment until deeper source collection runs.
Local clusters rerank extracted product concepts and description terms. The generated graph remains the fallback for sparse descriptions: offline reciprocal product-similarity graph: extracted concepts + description terms + bounded category/affiliation boosts. Minimum fallback score: 0; max competitors: 6.
Companies similar to Engage Bio
A deterministic local cluster built from offline product facets and meaningful description terms. Category and selected-institution affiliation provide bounded tie-breaks. Open any peer to continue exploring its cluster.
Granza Bio
match 33Granza Bio is developing programmable therapeutics for the immune system. Our platform is built on the foundational discovery of immune “superkiller” attack particles — the natural ammunition used by cytotoxic immune cells to deliver potent, localized killing. By re-arming exhausted immune cells with newly programmed ammunition, Granza restores and enhances immune function. This approach enables a new class of treatments with the potential to transform diseases ranging from cancer to autoimmunit
shared product terms: bio, develop, clas, potent; shared affiliation: Y Combinator
Sensible Biotechnologies
match 25The future of mRNA therapeutics is hampered by manufacturing challenges and unless solved, its exciting potential may never be realised. Sensible enables the next generation of mRNA medicines by turning living cells into factories producing abundant, highly stable and non-immunogenic mRNA in a scalable and cost-effective way.
shared product terms: non, scalable, medicine; shared affiliation: Y Combinator
Ochre Bio
match 25Ochre Bio is a biotechnology company developing RNA medicines for chronic liver diseases.
shared product terms: bio, develop, medicine; shared affiliation: Y Combinator
Luminist Labs
match 25Luminist developed a non-invasive diagnostic test for the early detection and staging of liver fibrosis and non-alcoholic steatohepatitis (NASH). Luminist was acquired in 2020 by DiscernDx.
shared product terms: develop, non, acquir; shared affiliation: Y Combinator
Nuntius Therapeutics
match 17Cell-specific genetic medicines
shared product terms: genetic, medicine; shared affiliation: Y Combinator
Embark Trucks
match 17Embark Technology develops self-driving truck software. Embark was the first self-driving truck company to achieve an autonomous coast-to-coast drive, the first to reach 100,000 miles driven on public roads, and the first to open a network of transfer points. Embark went public on NASDAQ in 2021 and was acquired by Applied Intuition in 2023.
shared product terms: develop, acquir; shared affiliation: Y Combinator